10.1 Kentucky KASPER Reporting Requirements
Key Takeaways
- KASPER is Kentucky's electronic prescription monitoring program administered by the Cabinet for Health and Family Services (CHFS) / Office of Inspector General (OIG) pursuant to KRS 218A.202 and 902 KAR 55:110.
- Dispensing dispensers must electronically report all Schedule II, III, IV, and V controlled substances dispensed in Kentucky within one (1) business day (or 24 hours) of dispensing.
- Kentucky mandates reporting for state-specific scheduled drugs that are non-controlled federally, notably Gabapentin (classified as a Schedule V controlled substance in KY since July 2017) and butalbital combination products without codeine (Fioricet, classified as Schedule III in KY).
- Pharmacies must transmit comprehensive dispensing data including patient identifiers (full name, address, DOB, SSN or alternative government ID), drug NDC, metric quantity, days supply, dates written and filled, serial number, prescriber DEA/NPI, pharmacy DEA/NPI, and payment method code.
- Statutory reporting exemptions are narrowly restricted to inpatient hospital administration, LTCF administration directly to residents, and emergency department dispensing of a 48-hour supply or less; pharmacies open for business that dispense zero controlled substances must transmit a daily zero-report.
10.1 Kentucky KASPER Reporting Requirements
The Kentucky All Schedule Prescription Electronic Reporting (KASPER) system is the Commonwealth's electronic Prescription Drug Monitoring Program (PDMP). Established by the Kentucky General Assembly in 1998 and significantly expanded under landmark legislation including 2012 House Bill 1 (HB 1) and 2017 House Bill 333, KASPER serves as a real-time clinical and regulatory tracking system designed to curb the diversion, abuse, and misuse of controlled substances while preserving legitimate medical access for patients in pain.
Under Kentucky law, the operation of KASPER and mandatory dispenser reporting are codified in KRS 218A.202 and implemented through administrative regulations promulgated by the Cabinet for Health and Family Services under 902 KAR 55:110.
1. Statutory Authority, Regulatory Architecture & Administration
To ensure rigorous oversight across healthcare and law enforcement domains, the administration of KASPER is vested in the executive branch of state government:
┌─────────────────────────────────────────────────────────────────────────────┐
│ KASPER ADMINISTRATIVE ARCHITECTURE │
├─────────────────────────────────────────────────────────────────────────────┤
│ STATUTORY JURISDICTION: KRS Chapter 218A (Uniform Controlled Substances Act)│
│ • KRS 218A.202: Codifies KASPER establishment, reporting duties, authorized │
│ querying access, confidentiality protections, and criminal penalties. │
│ │
│ ADMINISTRATIVE JURISDICTION: 902 KAR Chapter 55 │
│ • 902 KAR 55:110: Details technical electronic transmission formats (ASAP), │
│ mandatory data fields, error correction windows, and zero-reporting rules.│
│ │
│ REGULATORY AGENCY: │
│ • Cabinet for Health and Family Services (CHFS) │
│ • Administered specifically through the Office of Inspector General (OIG), │
│ Division of Certificate of Need and Licensing / Drug Enforcement and │
│ Professional Practices Branch in Frankfort, Kentucky. │
│ │
│ INTER-AGENCY COLLABORATION: │
│ • CHFS/OIG coordinates with the Kentucky Board of Pharmacy (KBOP), the │
│ Kentucky Board of Medical Licensure (KBML), Kentucky Board of Nursing, │
│ and law enforcement agencies (KSP, Attorney General, DEA). │
└─────────────────────────────────────────────────────────────────────────────┘
The Mandatory Dispenser Standard
Under KRS 218A.202, any dispenser—defined as any licensed community pharmacy, clinic, out-of-state mail-order pharmacy holding a Kentucky non-resident permit, or dispensing practitioner that delivers a controlled substance to an ultimate user in Kentucky—SHALL electronically transmit complete dispensing data to KASPER.
2. Scope of Controlled Substances Reported to KASPER
A critical high-yield focus on the Kentucky MPJE is the precise statutory scope of drugs subject to mandatory reporting. Under KRS 218A.202(1) and 902 KAR 55:110, reporting is required for:
Unlike some jurisdictions that only capture Schedule II opioids, Kentucky mandates comprehensive surveillance across all five controlled substance tiers. Furthermore, candidates must master Kentucky's state-specific scheduling classifications, which exceed federal Controlled Substances Act baselines:
| Controlled Substance Category | Kentucky Scheduling Classification | Federal Scheduling Classification | KASPER Reporting Status |
|---|---|---|---|
| Schedule II Opioids & Stimulants (e.g., Oxycodone, Hydrocodone, Morphine, Fentanyl, Adderall, Ritalin) | Schedule II (C-II) | Schedule II (C-II) | MANDATORY reporting within 1 business day. |
| Schedule III Anabolic Steroids & Opioid Combos (e.g., Suboxone / Buprenorphine, Tylenol with Codeine) | Schedule III (C-III) | Schedule III (C-III) | MANDATORY reporting within 1 business day. |
| Butalbital Combinations without Codeine (e.g., Fioricet, Butalbital/APAP/Caffeine) | Schedule III (C-III)<br/>(902 KAR 55:015 / 55:045) | Exempt / Non-Controlled federally (due to APAP ratio) | MANDATORY reporting. Kentucky classifies all butalbital products as C-III! |
| Schedule IV Benzodiazepines & Sedatives (e.g., Alprazolam, Clonazepam, Zolpidem, Tramadol) | Schedule IV (C-IV) | Schedule IV (C-IV) | MANDATORY reporting within 1 business day. |
| Gabapentin (Neurontin) | Schedule V (C-V)<br/>(902 KAR 55:110 / KRS 218A.020) | Non-Controlled federally | MANDATORY reporting. Rescheduled to C-V in KY effective July 1, 2017! |
| Schedule V Antitussives & Antidiarrheals (e.g., Promethazine with Codeine, Lomotil, Pregabalin/Lyrica) | Schedule V (C-V) | Schedule V (C-V) | MANDATORY reporting within 1 business day. |
Exam Alert — Gabapentin & Fioricet Scheduling Traps:
- Gabapentin: Federally, gabapentin is a non-controlled legend drug. In Kentucky, gabapentin is a Schedule V controlled substance. Every dispensing of gabapentin (capsules, tablets, solution) must be reported to KASPER within 1 business day, requires a valid controlled substance prescription, and is subject to Kentucky's C-III through C-V refill limit (maximum 5 refills / 6-month expiration).
- Fioricet (Butalbital/APAP/Caffeine): While exempt from federal scheduling, Kentucky administrative regulations schedule all butalbital combinations as Schedule III controlled substances. Dispensing Fioricet requires full KASPER transmission, Kentucky security blanks for written orders, and compliance with C-III dispensing limits.
3. Reporting Timelines, Daily Zero-Reports & Error Correction
To ensure KASPER maintains real-time utility for clinical decision-making and law enforcement surveillance, Kentucky enforces strict transmission deadlines and data integrity protocols under 902 KAR 55:110:
┌─────────────────────────────────────────────────────────────────────────────┐
│ KASPER TRANSMISSION DEADLINES & COMPLIANCE RULES │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Mandatory Reporting Timeline: │
│ • Data MUST be transmitted within ONE (1) BUSINESS DAY of the date the │
│ controlled substance was dispensed. │
│ • 'Dispensed' occurs when the medication is delivered to the patient or │
│ patient's agent (or placed in the mail/courier system). │
│ │
│ 2. Electronic Transmission Standard: │
│ • Transmissions must conform to the American Society for Automation in │
│ Pharmacy (ASAP) standard format for prescription monitoring systems. │
│ • Secure electronic submission via KASPER web portal or sFTP. │
│ │
│ 3. Daily Zero-Reporting Mandate: │
│ • If a pharmacy is OPEN for business on a normal operating day but │
│ dispenses ZERO (0) Schedule II–V controlled substances, a │
│ 'Zero-Report' (null report) MUST be submitted to KASPER. │
│ • Prevents blind spots in regulatory surveillance and confirms that the │
│ pharmacy did not experience technical communication failures. │
│ │
│ 4. Error Correction & Resubmission Window: │
│ • When KASPER rejects a transaction record (e.g., mismatch in patient │
│ identifiers, invalid DEA/NPI, or faulty NDC code), the dispenser must │
│ correct the error and resubmit the record within statutory deadlines │
│ (promptly, not to exceed 7 calendar days from notification). │
└─────────────────────────────────────────────────────────────────────────────┘
4. Mandatory KASPER Reporting Data Elements
Under 902 KAR 55:110, Section 1, for every individual controlled substance dispensing event, the dispensing pharmacy must transmit an electronic record containing all of the following data fields:
| Data Category | Specific Required Field | Legal & Clinical Significance |
|---|---|---|
| Patient Identification | • Full Legal Name (Last, First, Middle)<br/>• Residential Address (Street, City, State, ZIP)<br/>• Date of Birth (DOB)<br/>• Social Security Number (SSN) or Valid Alternative ID | Uniquely identifies the patient across multiple healthcare systems and pharmacies to aggregate multi-facility dispensing histories. |
| Alternative Patient ID | • State Driver's License Number, or<br/>• State-issued ID Card Number, or<br/>• Passport Number, or<br/>• Military / Veteran ID Number | If a patient has no SSN (e.g., minor child, foreign national, or unassigned), an approved government ID number must be recorded. If child has no ID, parent/guardian ID is utilized. |
| Drug Identification | • 11-digit National Drug Code (NDC) of the actual product dispensed | Identifies exact chemical entity, strength, dosage form, and manufacturer. |
| Quantity & Days Supply | • Metric Quantity Dispensed (count, mL, grams)<br/>• Estimated Days Supply | Required to calculate daily Morphine Milligram Equivalents (MME) and detect rapid early refills or overlapping therapies. |
| Dispensing Chronology | • Date Prescription Was Written (Issued)<br/>• Date Prescription Was Dispensed (Filled) | Enables calculation of prescription age, 60-day C-II expiration windows, and prescriber-to-fill lag time. |
| Prescription Tracking | • Prescription Serial Number (Rx Number)<br/>• New vs. Refill Indicator & Refill Number | Tracks specific prescription authorizations and lifecycle refills. |
| Prescriber Identifiers | • Prescriber DEA Registration Number<br/>• Prescriber National Provider Identifier (NPI) | Authenticates federal prescribing registration and individual provider identity. |
| Pharmacy Identifiers | • Dispensing Pharmacy DEA Registration Number<br/>• Dispensing Pharmacy NPI Number | Identifies licensed dispensing facility and geographic location. |
| Method of Payment | • Payment Method Code:<br/> - Cash / Private Out-of-Pocket<br/> - Commercial Private Insurance<br/> - Kentucky Medicaid / MCO<br/> - Medicare Part D<br/> - Workers' Compensation / Other | High-Yield Red Flag Identifier: Tracks cash payments used to bypass insurance-based prospective DUR or conceal doctor shopping. |
5. Statutory Exemptions from KASPER Reporting
Under KRS 218A.202(3), the General Assembly established three narrow, explicit exemptions where controlled substance administration or dispensing is NOT required to be transmitted to KASPER:
┌─────────────────────────────────────────────────────────────────────────────┐
│ STATUTORY EXEMPTIONS FROM KASPER REPORTING │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Inpatient Institutional Administration: │
│ • Controlled substances administered directly to a patient admitted as an│
│ inpatient in a licensed hospital, surgical center, or hospice facility.│
│ │
│ 2. Direct Long-Term Care Facility (LTCF) Administration: │
│ • Controlled substances administered directly to an inpatient resident of│
│ a licensed nursing facility, intermediate care facility, or LTCF. │
│ • EXAM DISTINCTION: Outpatient or closed-door retail pharmacies that │
│ dispense labeled prescription vials/blister packs delivered to an LTCF │
│ MUST report the dispensing to KASPER. Direct administration from floor │
│ stock / institutional emergency supply is exempt. │
│ │
│ 3. Emergency Department 48-Hour Discharge Dispensing: │
│ • Controlled substances dispensed directly by an emergency room medical │
│ practitioner to an ER patient upon discharge in an amount NOT │
│ EXCEEDING a FORTY-EIGHT (48) HOUR SUPPLY. │
│ • If an ER practitioner issues a written/electronic prescription to be │
│ filled at an outpatient community pharmacy, that community pharmacy │
│ MUST report the dispensing to KASPER! │
└─────────────────────────────────────────────────────────────────────────────┘
6. High-Yield Clinical Scenarios & Common Exam Traps
Scenario 1: The Out-of-State Mail Order Pharmacy
A large mail-order pharmacy located in Ohio dispenses a 30-day supply of lisdexamfetamine (Vyvanse, C-II) and delivers it via FedEx to a resident in Covington, Kentucky. Must this Ohio pharmacy report the transaction to KASPER?
- Legal Analysis: YES. Under KRS 218A.202, any out-of-state pharmacy holding a Kentucky Board of Pharmacy non-resident pharmacy permit that dispenses and delivers a controlled substance to a Kentucky resident must report the dispensing data to KASPER within one (1) business day.
Scenario 2: Hospital Emergency Room Dispensing vs. Community Fill
An emergency department physician treats a patient with an acute fracture on Friday evening. The physician hands the patient a 48-hour starter pack of hydrocodone/acetaminophen (12 tablets) directly from ER supply, and writes a prescription for a 3-day supply to be filled at a 24-hour retail pharmacy.
- Legal Analysis: The hospital ER does not report the 48-hour starter pack to KASPER under the KRS 218A.202(3) emergency room exemption. However, when the patient presents the 3-day supply prescription to the outpatient retail pharmacy, the retail pharmacy must report the dispensing to KASPER within one business day.
A community pharmacy in Paducah is open for regular business operations on Wednesday from 8:00 AM to 8:00 PM. During that entire business day, the pharmacy dispenses 142 non-controlled maintenance medications, 12 OTC items, but zero (0) Schedule II, III, IV, or V controlled substances. Which of the following statements correctly states the pharmacy's legal obligation under 902 KAR 55:110?
A staff pharmacist in Lexington is reviewing prescriptions ready for transmission to KASPER. Which of the following medications dispensed by the pharmacy is EXEMPT from KASPER electronic reporting under Kentucky law?
Under KRS 218A.202 and 902 KAR 55:110, which of the following lists contains ONLY data elements that are MANDATORY for a dispensing pharmacy to transmit to KASPER for every controlled substance prescription?